Overview
Adelphi Real World provides leadership in real world evidence across 25+ years of experience, delivering insights from physicians, patients, caregivers, and payers through Disease Specific Programmes (DSPs), tailored non-interventional studies, and international database analyses. Its products generate real-world data that inform health outcomes, medical affairs, market access, and other functions throughout a product’s lifecycle. The company differentiates itself with a mix of DSPs and Bespoke solutions, broad stakeholder perspectives, and end-to-end evidence generation across a global footprint. Its goal is to provide actionable, real-world evidence that helps organizations make informed decisions and improve outcomes across a product’s lifecycle.
Work here?Claim your company
Simplify's take
What believers are saying
- 2026 papers in alopecia, atopic dermatitis, and HAE show continued sponsor demand.
- Cytokinetics presented an Adelphi DSP analysis at ESC Heart Failure 2026.
- Omnicom's 2025 Interpublic acquisition broadens cross-sell opportunities inside the enlarged health network.
What critics are saying
- Pharma can switch spending to IQVIA, Evidera, or OM1 when DSPs commoditize.
- DSP studies are cross-sectional; they miss longitudinal outcomes and invite payer skepticism quickly.
- If sponsors migrate to claims and EHR platforms, Adelphi's survey model dies.
What makes Adelphi Real World unique
- Adelphi Real World owns Disease Specific Programmes pairing physicians and patients across 100 disease areas.
- Its surveys span countries and capture treatment patterns, satisfaction, and decision-making in one dataset.
- Omnicom Health backs distribution, giving Adelphi reach inside large pharma accounts worldwide.
Help us improve and share your feedback! Did you find this helpful?